COPD nDPIA 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease

125/25 mcg once-daily GSK573719/GW642444

125mcg once-daily GSK573719

Placebo once-daily

Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE)

Number of Participants With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Over the Course of the 52-week Treatment Period

Time to the First On-treatment COPD Exacerbation

Number of Participants With the Indicated ECG Result Interpretations at Any Time Post-Baseline

Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) at Months 3, 6, 9, and 12

Change From Baseline in Albumin, Total Protein, and Hemoglobin at Months 3, 6, 9, and 12

Change From Baseline in Calcium, Carbon Dioxide (CO2) Content/Bicarbonate, Chloride, Glucose, Inorganic Phosphorus (IP), Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Months 3, 6, 9, and 12

Change From Baseline in Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Uric Acid at Months 3, 6, 9, and 12

Change From Baseline in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Segmented Neutrophils in Blood at Months 3, 6, 9, and 12

Change From Baseline in Eosinophil Count, Platelet Count, and White Blood Cell (WBC) Count at Months 3, 6, 9, and 12

Change From Baseline in Hematocrit at Months 3, 6, 9, and 12

Change From Baseline to Maximum Systolic Blood Pressure (SBP) and Change From Baseline to Minimum Diastolic Blood Pressure (DBP) Over the Course of the 52-week Treatment Period

Maximum Change From Baseline in Pulse Rate Over the Course of the 52-week Treatment Period

Maximum Change From Baseline in the Electrocardiogram (ECG) Parameters of QT Interval Corrected for Heart Rate by Bazett's Formula (QTcB), QT Interval Corrected for Heart Rate by Fridericia's Formula (QTcF), and PR Interval Over the Course of the 52-week

Maximum Change From Baseline in the ECG Parameter of Heart Rate Over the Course of the 52-week Treatment Period

Number of Participants With the Indicated Change From Screening to Any Time Post-Baseline in Holter ECG Interpretation

Change From Baseline in the Mean Number of Puffs of Rescue Medication (Salbutamol and/or Ipratropium Bromide) Per Day Over the Course of the 52-week Treatment Period

Change From Baseline in the Percentage of Rescue-free Days Over the Course of the 52-week Treatment Period

Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at Months 1, 3, 6, 9, and 12